« Return to News | Drug Sponsors | Ethics/Regulatory

Novartis recalls OTC drugs, temporarily closes U.S. plant

Monday, January 9, 2012 01:51 PM

Novartis is recalling several over-the-counter products such as Gas-X, Excedrin, NoDoz, and Bufferin due to inconsistent bottling, as well as broken gel caps and chipped pills.

“Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended,” Novartis stated. “This could potentially result in overdose, interaction with other medications a consumer may be taking or an allergic reaction.”

The recall began the day after the FDA released a 13-page Form 483, which cited Novartis’ repeated failures to follow up on quality concerns voiced by patients. The company also failed to inform the FDA of these complaints. Issues raised in the 483 were identified in the summers of 2010 and 2011.

In addition to recalling its products, Novartis temporarily shut down its Lincoln, Neb., plant to fix and improve its manufacturing activities, expecting a $120 million one-time charge.

A full list of products and recall dates can be found at www.novartisOTC.com.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.